The Cotara story
Cotara was once this company's shining jewel, and maybe within one year will be once again, well, besides bavi of course. The problem for PPHM with Cotara was that they got it all the way to P3 and then ran out of money. They could not advance Cotara further without a partner (or money) so they dumped all of their remaining resources into the Bavituximab and 2C3 programs while shelving Cotara. Your next question is why did they have to shelve Cotara, why couldn't they find a partner? This is 4 years ago. The landscape for radiopharmas was much different then.
You see, when you are an oncologist and someone comes to you with GBM, you will treat it with chemo and all other available options. Once you send a patient to a radiologist (the only one able to administer Cotara) you lose the patient and his business. Why would large pharma fork over all this money for a drug they knew oncologists would snub? You see now, that was the problem. Now we have organizations like NABTT running the trials and other companies that are pushing radiopharmas again. They are becoming accepted-finally.Just a month or two back a company went public with two radio pharmas (molecular sciences symbol MIPI) in a phase 2 and the market gave them a $350M market cap. Again, MIPI has two radiopharmas in phase 2. PPHM at this price once they enter Phase 2 with Cotara in India is insanely undervalued IMO. PPHM needs a 3rd party, either Wall Street analysts or big academic or better yet large pharma to endorse the Cotara and Bavi platforms and PPHM will pull a Dendreon in one day. PPHM still remains an undiscovered jewel IMO. When will they come for it? As soon as that 3rd party comes in to play. Until then it is anyones guess with the way the shorts are active in this issue these days. Hope this helps.
AI
Market Data 
Markets 
